Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial

Atypical meningioma is a tumour that arises from the lining of the brain. It mostly affects adults, with most patients in the 40-60 year age group. The primary treatment for atypical meningioma is surgical removal, but with surgery alone up to 40% of patients will experience recurrence. Because of this risk, some clinicians give early radiotherapy, whilst others advise regular monitoring with radiotherapy given only at recurrence. Currently there is no consensus as to which of these two approaches is best. This randomised controlled trial will compare the two approaches, and aims to determine whether early radiotherapy reduces the risk of tumour recurrence compared to regular monitoring in newly diagnosed atypical meningioma.

Primary Sponsor

The Walton Centre NHS Foundation Trust, University of Liverpool, UK

Collaborating Groups

European Organisation for Research and Treatment of Cancer (EORTC) ; Trans Tasman Radiation Oncology Group (TROG)

Final Accrual

15

Closing Date of Accrual

May 2021

Trial Chairperson

Dr Neda Haghighi, Peter MacCallum Cancer Centre, VIC

Trial Contact

ROAM@trog.com.au

Related Post

11 June, 2025

Trial Could Prove a Game-Changer for Treating High-Risk Skin Cancer

LATEST NEWS: 11 JUNE 2025 New findings from a

Grant for PRIME-Lung trial
10 June, 2025

MRFF $1.5m grant for TROG-sponsored trial of new approach in lung cancer

LATEST NEWS: 10 JUNE 2025 A trial of a